Gerhard Gründer, Prof Dr

Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Task Force “Therapeutic Drug Monitoring”

JCP
Therapeutic Reference Range for Olanzapine
Systematic Review

July 19, 2023

A therapeutic reference range of 20–40 ng/mL for oral and long-acting injectable olanzapine yields optimal treatment effects in schizophrenia spectrum disorders. Dose reduction is not needed above 40 ng/mL...
Katja Wesner, Christoph Hiemke, Niels Bergemann, et al
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
Georgios Schoretsanitis, John M. Kane, Christoph U. Correll, et al
JCP
Original Research

November 26, 2019

Risperidone is mainly metabolized hepatically to its metabolite 9-hydroxyrisperidone (9-OH-RIS), which is excreted renally. This study examined how kidney function affects serum concentrations of risperidone and 9-OH-RIS in a...
Philipp Gründer, Marc Augustin, Michael Paulzen, et al
JCP
Original Research

September 4, 2018

Cigarette smoking is common among individuals depression, and smoking can affect the metabolism of antidepressant medications. Read this article to learn dosing strategies that physicians can employ when treating...
Marc Augustin, Georgios Schoretsanitis, Christoph Hiemke, et al
JCP
Original Research

August 19, 2014

Michael Paulzen, Sarah Groppe, Simone C. Tauber, et al
JCP
Case Report

November 15, 2011

Michael Paulzen, Simone C. Tauber, André Kirner-Veselinovic, et al
JCP
Letter to the Editor

September 30, 2008

Michael Paulzen, Gerhard Gründer

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe